Greenland Mines (NASDAQ: GRML) is streamlining its operations to become a dedicated rare earths and critical minerals company, with a series of corporate moves announced on September 8, 2026. The company will spin off its biotechnology division in the fourth quarter of 2026, a strategic step that underscores its commitment to the mining sector. This transition follows Nasdaq's formal approval of the company's application related to its March 2026 transaction, resolving prior deficiencies and ensuring full compliance with listing requirements.
The company has also completed the acquisition of the Sarfartoq project in Greenland, which received approval from the Government of Greenland on September 1. An independent S-K 1300 Initial Assessment for the ST1 deposit at Sarfartoq revealed a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. This assessment highlights the project's potential to produce neodymium-praseodymium (NdPr) oxide, a critical component for permanent magnets used in electric vehicles and wind turbines. Planned annual NdPr oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China, based on 2025 consumption levels, during each of the project's nine scheduled operating years. This positions Greenland Mines as a significant player in the non-Chinese rare earth supply chain, which is vital for Western economies seeking to reduce dependency on Chinese exports.
In a move to strengthen its board for the upcoming challenges, Greenland Mines announced the resignation of Riad El-Dada and Dr. Shalom Hirschman, replaced by capital markets veteran Jason Hawkins. Hawkins' experience is expected to guide the company as it advances the Sarfartoq and Skaergaard projects. The Skaergaard project, located in southeast Greenland, is a palladium-gold-platinum deposit that adds further diversification to the company's portfolio.
The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities. This aligns with its broader North Atlantic Critical Metals Corridor vision, which aims to link Greenland resources with allied downstream jurisdictions and industrial infrastructure. The spin-off of the biotech division, which includes Klotho's KLTO-202 treatment for ALS, will allow each entity to focus on its core operations, potentially unlocking shareholder value.
Investors and analysts will likely view these developments as a positive catalyst for Greenland Mines, as the company sharpens its focus on critical minerals that are essential for the global energy transition. The Sarfartoq project's robust economics and the strategic board refresh signal a clear direction under the company's new leadership. As Greenland Mines progresses, it will be crucial to monitor the execution of the spin-off and the development timelines for its mining projects.
For more information on these developments, the full press release is available at https://ibn.fm/QN1U9. The latest news and updates relating to GRML can be found in the company's newsroom at https://ibn.fm/GRML.
